Recent News
WordPress database error: [Got error 28 from table handler]
SELECT SQL_CALC_FOUND_ROWS z02_posts.* FROM z02_posts LEFT JOIN z02_post2cat ON (z02_posts.ID = z02_post2cat.post_id) WHERE 1=1 AND z02_post2cat.category_id IN (3) AND (post_type = 'post' AND (post_status = 'publish')) GROUP BY z02_posts.ID ORDER BY post_date DESC LIMIT 0, 2
At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.
We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. Our lead product candidate, sumatriptan DosePro™, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. We submitted a New Drug Application, or NDA, with the U.S. Food and Drug Administration, or FDA, for sumatriptan DosePro in December 2007, and it was accepted for filing by the FDA in March 2008. If sumatriptan DosePro is approved by the FDA, we intend to build our own focused sales force in the U.S. and launch the product in the first quarter of 2009. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. This product candidate has completed Phase 2 clinical trials, and we anticipate initiating the Phase 3 clinical program in the second half of 2008.
sumatriptan DosePro™
